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Bacteria for Defense
Previous studies reported that 
Staphylococcus epidermidis on 
the skin produces antimicrobial 
peptides to inhibit pathogenic 
organisms and modulates 
inflammation through Toll-
like receptors (TLRs). Lai and 
colleagues found that molecules 
secreted by S. epidermidis 
increased the expression of 
β-defensins 2 and 3 in murine 
skin and undifferentiated 
human keratinocytes, rendering 
these cells more resistant to 
certain pathogens via a TLR2-
dependent mechanism. Thus, 
this commensal bacterium 
induces antimicrobial peptide 
expression and enables the 
skin to mount an enhanced 
immune response. These 
findings highlight potential 
pitfalls of using antimicrobial 
agents indiscriminately to fight 
infections. See page 2211
Pervasive 
Heterogeneity
T-cell-receptor monoclonality 
was previously considered 
dogma for lymphomas, 
especially cutaneous T-cell 
lymphomas such as Sézary 
syndrome (SS). Using GeneScan 
analysis to investigate skin 
and blood samples from SS 
patients, Fierro and colleagues 
demonstrated that clonal 
heterogeneity was more 
frequent than homogeneity. 
Importantly, the presence of an 
oligoclonal pattern in the skin 
correlated with a longer survival 
time, and the appearance of new 
oligoclones during treatment 
was associated with a stronger 
response to extracorporeal 
photochemotherapy, suggesting 
that detection of heterogeneity 
will be useful in making 
prognosis and treatment 
decisions for SS patients.  
See page 2312
Role of Riluzole
The majority of human melanomas ectopi-
cally express the metabotropic glutamate 
receptor-1 (GRM1), and inhibition of this 
receptor with riluzole has proved useful 
in blockade of mitogen-activated protein 
kinase and phosphatidylinositol-3-kinase/
AKT signaling and involution of tumors in 
patients. Le and colleagues discovered that 
treatment of human melanoma cell lines 
with the glutamate release inhibitor riluzole 
or the specific GRM1 agonist BAY 36-7620 
attenuated melanoma cell transformation via a decrease in migration, invasion, and 
proliferation of these cells, suggesting that these effects likely occur through block-
ade of GRM1 signaling. These mechanistic results pave the way for the develop-
ment of riluzole-based combination therapies. See page 2240
Persistently Activated Epidermis
Complex interactions among immune 
cells, endothelial cells, and fibro-
blasts contribute to pathogenic fibrot-
ic events in systemic sclerosis (SSc). 
Aden and colleagues found abnormal 
activation of the epidermis in SSc. 
Also, IL-1α, which initiates kerati-
nocyte activation following injury, 
was increased. Stress signaling via 
the IL-1α downstream factors MAPK, 
c-Jun, and p38 was also induced in 
SSc epidermis. Together, these find-
ings indicate that IL-1α antagonism 
may offer a therapeutic mechanism to 
block epithelial–fibroblast interactions to reduce persistent fibroblast activation and 
subsequent debilitating fibrosis in SSc patients. See page 2191
Differential Irritation
Irritant contact dermatitis (ICD) most often results from repeated 
exposure to weak irritants. In a genome-wide expression analy-
sis of irritated human epidermis using microarrays representing 
47,000 transcripts, Clemmensen and colleagues found that dif-
ferent pathways were activated in the epidermis in response to 
exposure to nonanoic acid or sodium lauryl sulfate. Analysis 
of early and late time points revealed that most of the early-
response genes were quickly turned off, supporting the notion 
that the effects of chronic exposure cannot be extrapolated 
from studies of acute exposure. Furthermore, 23 potential bio-
markers common to cumulative skin irritation were identified, 
and these transcripts offer a starting point for further studies of 
the mechanisms of ICD. See page 2201
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